Scarica l'app Stockscreener
52.84
1.35%
-0.725
Pre-mercato:
50.66
-2.185
-4.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$53.57
Aprire:
$52.42
Volume 24 ore:
9.41M
Relative Volume:
0.83
Capitalizzazione di mercato:
$20.65B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-6.0533
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+5.08%
1M Prestazione:
+24.20%
6M Prestazione:
+118.46%
1 anno Prestazione:
+70.69%
Intervallo 1D:
$50.45
$54.94
Intervallo di 1 settimana:
$49.53
$54.94
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
52.84 | 20.93B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna Stock (MRNA) Opinions on Piper Sandler Price Target Hike - Quiver Quantitative
Moderna, Inc. $MRNA Shares Purchased by Banco Santander S.A. - MarketBeat
Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus - Yahoo Finance
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
European health agency recommends approving Moderna’s combined flu, COVID vaccine - The Hill
This Is What Whales Are Betting On Moderna - Benzinga
Europe just approved a combined flu and COVID shot. Why hasn’t the US? - Fast Company
Moderna’s combination flu, COVID shot wins over European drug regulators - BioPharma Dive
Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating - marketscreener.com
Uncertainty Looms Over Pharma’s Legal Strategy as States Challenge New Vaccine Schedule - BioSpace
Moderna (MRNA) Gains EMA Recommendation for Combo Vaccine - GuruFocus
Why Is Moderna Stock Moving Today? Europe Clears Moderna’s Dual Vaccine - Tokenist
EU regulator backs approval for Moderna’s combined COVID, flu shot - WTVB
EU regulator backs approval for Moderna's combined COVID and flu vaccine - marketscreener.com
Moderna Gets EU Approval for mRNA Combination Covid-Flu Shot - Bloomberg
Moderna’s flu-COVID combo vaccine gets EU regulatory backing By Investing.com - Investing.com India
Moderna Says It Received Positive EU Panel Opinion for Flu-COVID Combination Vaccine - marketscreener.com
Moderna (MRNA) Gains Positive Opinion for Combo Vaccine in EU - GuruFocus
Moderna (MRNA) Nears EU Approval for Combined Flu and COVID-19 V - GuruFocus
Moderna’s Covid-Flu Vaccine Recommended for Approval in EU - WSJ
Moderna gets EU approval for mRNA combination Covid-flu shot - Moneycontrol.com
Moderna’s flu-COVID combo vaccine gets EU regulatory backing - Investing.com
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - ACCESS Newswire
World’s first flu-COVID combo shot wins key EU backing for over-50s - Stock Titan
Moderna Wins European Medicines Agency's Positive Opinion for Combined COVID-19, Influenza Vaccine - marketscreener.com
Ema recommends granting marketing authorisation in EU for mCombriax - marketscreener.com
Moderna (MRNA) Is Up 10.2% After FDA Accepts Full Review Of Its mRNA Flu Vaccine - simplywall.st
Analyst recommendations: Spotify, Gartner, Godaddy, Medline, Moderna… - marketscreener.com
Moderna (MRNA) Stock Review: Performance & Valuation Concerns in 2026News and Statistics - IndexBox
Moderna president Hoge sells $7.8m in MRNA stock - Investing.com South Africa
Moderna president Hoge sells $7.8m in MRNA stock By Investing.com - Investing.com Canada
Stephen Hoge Sells 160,009 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
Moderna Royalty Opinion Loss Raises Covid-Shot Trial Stakes (1) - Bloomberg Law News
Moderna's Damages Expert Limited In March Patent Trial - Law360
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - Nasdaq
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - The Motley Fool
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead - Finviz
A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound - Yahoo Finance
MRNA Stock Surges 26% With A 7-day Winning Spree On FDA Flu Vaccine Review - Trefis
How To Read FDA's Flip-Flop On Moderna Flu Vaccine - Law360
What the Options Market Tells Us About ModernaModerna (NASDAQ:MRNA) - Benzinga
Moderna says FDA will consider its new flu shot after resolving public dispute - Devils Lake Journal
Moderna Stock: How Far Can The Flu Shot Fly? - Forbes
FDA Moderna review sets up pivotal test for mRNA flu jabs - The Pharma Letter
Will the FDA yank mRNA vaccines? - PharmaVoice
Moderna Shares Surge on Stronger-Than-Expected Revenue and Strategic Pivot - AD HOC NEWS
MRNA Stock Surges 25% With A 6-day Winning Spree On FDA Flu Shot Review - Trefis
Gilead’s Arcellx buy. Plus: ctDNA as surrogate endpoint — a BioCentury podcast - biocentury.com
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost - marketscreener.com
Moderna, Inc. (MRNA) Stock Analysis: Navigating a -15.68% Potential Downside Amid Revenue Challenges - DirectorsTalk Interviews
Moderna Faces New Challenges and Opportunities Ahead - Intellectia AI
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.73%
2.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):